AstraZeneca prices a $2 billion bond issue

AstraZeneca prices a $2 billion bond issue

AstraZeneca PLC announces that yesterday it conducted a successful global bond
market transaction issuing a total of $2 billion of notes. The proceeds of the
issue will be used for debt refinancing and general corporate purposes. The
transaction, which is an SEC-registered global offering, consists of two

$1 billion of 7-year fixed rate notes with a coupon of 1.95% and $1 billion of
30-year fixed rate notes with a coupon of 4%.
The notes will be issued under AstraZeneca’s existing automatic shelf
registration statement on Form F-3, which AstraZeneca filed with the US
Securities and Exchange Commission on 21 December 2010. Such registration
statement provides for the offer and sale from time to time of an indeterminate
amount of AstraZeneca’s debt securities and includes a prospectus which
investors should read to obtain more complete information. The offering was made
solely by means of a written prospectus forming part of the registration

A copy of the final prospectus supplement and accompanying prospectus relating
to the offering can be obtained by contacting Goldman Sachs & Co. at +1 866 471
2526, HSBC Securities (USA) Inc at +1 866 811 8049, J.P. Morgan Securities LLC
at +1 212 834 4533 or Morgan Stanley & Co. LLC at +1 866 718 1649.

– ENDS –


This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialisation of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by millions
of patients worldwide. For more information please visit:


Media Enquiries

Esra Erkal-Paler                         +44 20 7604 8030

Ann-Leena Mikiver                     +46 70 742 88 36

Investor Enquiries UK

James Ward-Lilley                     +44 20 7604 8122 mob: +44 7785 432613

Karl Hård                                    +44 20 7604 8123 mob: +44 7789

Nicklas Westerholm                  +44 20 7604 8124 mob: +44 7585 404950

Investor Enquiries US

Ed Seage                                    +1 302 886 4065   mob: +1 302 373
Jorgen Winroth                           +1 212 579 0506   mob: +1 917 612 4043